title: Biocontainment design considerations for biopharmaceutical facilities.
abstract: This article highlights biocontainment design considerations for biopharmaceutical manufacturing facilities. The major focus of this report is on industry's use and interpretation of the regulations with specific design recommendations for a Biosafety Level 2--Large-Scale physical containment level as described by the National Institutes of Health Guidelines.
authors.affiliation: SmithKline Beecham Pharmaceuticals, King of Prussia, PA 19406.
authors.forename: S R
authors.initials: SR
authors.lastname: Miller
authors.forename: D
authors.initials: D
authors.lastname: Bergmann
mesh_terms: D000062:Accidents, Occupational / Q000517:prevention & control; D003264:Containment of Biohazards / Q000295:instrumentation / Q000379:methods* / Q000592:standards; D004493:Education; D004867:Equipment Design; D005160:Facility Design and Construction / Q000592:standards*; D007218:Industrial Microbiology / Q000331:legislation & jurisprudence / Q000592:standards*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000592:standards*; D014865:Waste Disposal, Fluid / Q000379:methods*